Literature DB >> 30873652

Indoles: metabolites produced by intestinal bacteria capable of controlling liver disease manifestation.

T Hendrikx1, B Schnabl1,2.   

Abstract

Alterations in the bacteria that reside in our gastrointestinal tract play a role in the pathogenesis and progression of many disorders including liver and gastrointestinal diseases. Both qualitative (composition) and quantitative (amount) changes in gut microbes are associated with increased susceptibility to liver disease. Importantly, the intestinal microbiota is involved in the regulation of many host signalling pathways via the generation of different metabolites. Hence, dysbiosis influences disease development and progression by directly affecting the host-bacteria metabolic interaction. Microbe-derived harmful metabolites can translocate to distant organs due to increased intestinal permeability as observed during dysbiosis. Contrary, certain bacterial metabolites such as tryptophan metabolites contribute to intestinal and systemic homeostasis. Here, we provide an overview of current evidence describing to what extent microbial metabolites modulate the development of chronic liver diseases such as alcoholic steatohepatitis and nonalcoholic fatty liver disease with a special emphasis on indoles.
© 2019 The Association for the Publication of the Journal of Internal Medicine.

Entities:  

Keywords:  dysbiosis; gut-liver axis; metabolome; tryptophan

Year:  2019        PMID: 30873652     DOI: 10.1111/joim.12892

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  32 in total

1.  Indole and Derivatives Modulate Biofilm Formation and Antibiotic Tolerance of Klebsiella pneumoniae.

Authors:  Thanachaporn Yaikhan; Manatsanan Chuerboon; Natchapol Tippayatham; Nateekarn Atimuttikul; Taiyeebah Nuidate; Mingkwan Yingkajorn; Aung Win Tun; Hansuk Buncherd; Natta Tansila
Journal:  Indian J Microbiol       Date:  2019-10-05       Impact factor: 2.461

Review 2.  Organoid technologies for the study of intestinal microbiota-host interactions.

Authors:  Valentina Bozzetti; Stefania Senger
Journal:  Trends Mol Med       Date:  2022-02-26       Impact factor: 11.951

3.  Cinnabarinic Acid Provides Hepatoprotection Against Nonalcoholic Fatty Liver Disease.

Authors:  Nikhil Y Patil; Iulia Rus; Emma Downing; Ashok Mandala; Jacob E Friedman; Aditya D Joshi
Journal:  J Pharmacol Exp Ther       Date:  2022-08-06       Impact factor: 4.402

Review 4.  Promises of microbiome-based therapies.

Authors:  Jasmohan S Bajaj; Siew C Ng; Bernd Schnabl
Journal:  J Hepatol       Date:  2022-06       Impact factor: 30.083

Review 5.  The gut microbiota in transplant patients.

Authors:  Pearlie P Chong; Andrew Y Koh
Journal:  Blood Rev       Date:  2019-08-29       Impact factor: 8.250

Review 6.  Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future.

Authors:  Sonja Lang; Bernd Schnabl
Journal:  Cell Host Microbe       Date:  2020-08-12       Impact factor: 21.023

Review 7.  Microbial Products and Metabolites Contributing to Alcohol-Related Liver Disease.

Authors:  Bei Gao; Atoosa Emami; Shilpa Nath; Bernd Schnabl
Journal:  Mol Nutr Food Res       Date:  2020-07-07       Impact factor: 5.914

8.  Somatization in patients with predominant diarrhoea irritable bowel syndrome: the role of the intestinal barrier function and integrity.

Authors:  Laura Prospero; Giuseppe Riezzo; Michele Linsalata; Antonella Orlando; Benedetta D'Attoma; Marta Di Masi; Manuela Martulli; Francesco Russo
Journal:  BMC Gastroenterol       Date:  2021-05-22       Impact factor: 3.067

9.  Colonic In Vitro Model Assessment of the Prebiotic Potential of Bread Fortified with Polyphenols Rich Olive Fiber.

Authors:  Lorenzo Nissen; Flavia Casciano; Elena Chiarello; Mattia Di Nunzio; Alessandra Bordoni; Andrea Gianotti
Journal:  Nutrients       Date:  2021-02-27       Impact factor: 5.717

10.  Hepatoprotective Effects of Indole, a Gut Microbial Metabolite, in Leptin-Deficient Obese Mice.

Authors:  Christelle Knudsen; Audrey M Neyrinck; Quentin Leyrolle; Pamela Baldin; Sophie Leclercq; Julie Rodriguez; Martin Beaumont; Patrice D Cani; Laure B Bindels; Nicolas Lanthier; Nathalie M Delzenne
Journal:  J Nutr       Date:  2021-06-01       Impact factor: 4.798

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.